Objective Solriamfetol (JZP‐110) is a selective dopamine and norepinephrine reuptake
inhibitor with wake‐promoting effects. This phase 3 study (NCT02348593) evaluated the …

Abstract Study Objectives: Nasal continuous positive airway pressure (nCPAP) usually
reduces sleepiness in patients with obstructive sleep apnea/hypopnea syndrome. However …

Background Modafinil is a novel wake-promoting agent approved by the FDA ameliorating
excessive daytime sleepiness (EDS) in three disorders: narcolepsy, shift work sleep disorder …

Modafinil (MOD) is a wakefulness-inducing compound prescribed for treatment of excessive
daytime sleepiness as a consequence of sleep disturbances such as shift work sleep …

OBJECTIVE: Armodafinil is the R-enantiomer of racemic modafinil and has a significantly
longer half-life than the S-enantiomer. This study evaluated armodafinil 150mg/day as an …

Modafinil is a wake-promoting agent that is pharmacologically different from other
stimulants. It has been investigated in healthy volunteers, and in individuals with clinical …

Background Patients with shift-work sleep disorder chronically have excessive sleepiness
during night work and insomnia when attempting to sleep during the day. We evaluated the …

Abstract▴ Armodafinil is the R-enantiomer of modafinil, a wake-promoting agent, that
primarily affects areas of the brain involved in controlling wakefulness.▴ Once-daily …

Objective: To evaluate the burden of illness of narcolepsy and assess the health-related
quality-of-life (HQL) effects of oral modafinil, a wake-promoting therapy for excessive …

Background: Some patients with obstructive sleep apnea/hypopnea syndrome (OSA/HS)
who are regular users of nasal continuous positive airway pressure (nCPAP) therapy …